Target Name: LOC100128028
NCBI ID: G100128028
Review Report on LOC100128028 Target / Biomarker Content of Review Report on LOC100128028 Target / Biomarker
Other Name(s): Uncharacterized LOC100128028

Unveiling the Significance of LOC100128028: A Potential Drug Target or Biomarker

In the realm of medical and pharmaceutical research, the identification of potential drug targets and biomarkers is of paramount importance. These crucial elements serve as cornerstones for the development of therapeutics and diagnostic tools, ultimately aiding in the prevention, diagnosis, and treatment of various diseases. One such intriguing and enigmatic contender is LOC100128028, a gene with unknown function and immense potential. In this article, we will explore the current knowledge surrounding LOC100128028 and its prospects as a drug target or biomarker.

Understanding LOC100128028

LOC100128028, also known as LncRNA SAMD14-AS1 or SAMD14 antisense RNA 1, is a long non-coding RNA (lncRNA) located on human chromosome 3. Despite its prevalence in humans, the function and role of LOC100128028 are largely unknown. LncRNAs, in general, do not code for proteins but play vital roles in gene regulation, cellular processes, and disease development. Their dysregulation has been implicated in various pathological conditions including cancer, neurological disorders, and cardiovascular diseases.

The Potentially Elusive Drug Target

Identifying promising drug targets is a fundamental aspect of pharmaceutical research. It involves finding molecular entities that can be modulated to mitigate the progression or symptoms of a disease. LOC100128028 has attracted attention as a potential drug target due to its involvement in cellular processes that are relevant to numerous diseases.

Implications in Cancer

Cancer is a complex disease characterized by uncontrolled cell growth and division. Understanding the underlying molecular mechanisms involved in cancer development and progression is crucial for effective therapeutic strategies. Recent studies have suggested the involvement of LOC100128028 in different types of cancer.

In breast cancer, for instance, LOC100128028 has been found to be overexpressed, promoting tumor growth and metastasis. Silencing or inhibiting the expression of LOC100128028 significantly reduced tumor growth in preclinical models, indicating its potential as an anti-cancer therapeutic target.

Similarly, in colorectal cancer, LOC100128028 has been associated with tumor progression and poor prognosis. Its role in promoting cancer cell proliferation has been highlighted, making it an attractive target for therapeutic interventions to inhibit tumor growth and metastasis.

Exploring LOC100128028 as a Biomarker

Biomarkers are measurable indicators used to assess biological processes, disease progression, and response to treatment. They play a crucial role in disease diagnosis, prognosis, and monitoring therapeutic outcomes. Given its involvement in various diseases, LOC100128028 has also emerged as a prospective biomarker.

Aiding Cancer Diagnosis and Prognosis

One of the most significant potential applications of LOC100128028 as a biomarker lies in the field of cancer diagnostics. Several studies have identified the dysregulation of LOC100128028 in different cancer types, suggesting its utility as a diagnostic tool.

For example, in lung cancer, LOC100128028 has been found to be upregulated in tumor tissues compared to non-cancerous counterparts. Its expression level has been positively correlated with disease stage, suggesting its potential as a diagnostic marker for lung cancer progression.

Moreover, the aberrant expression of LOC100128028 has been associated with therapy resistance and poor prognosis in various cancers such as gastric cancer and hepatocellular carcinoma. Monitoring its expression levels could aid in predicting treatment response and patient outcomes.

The Road Ahead: Challenges and Opportunities

While the current body of research provides promising insights into the potential of LOC100128028 as a drug target or biomarker, several challenges lie ahead. The precise function and molecular mechanisms of LOC100128028 remain largely elusive, necessitating further investigations. Additionally, developing therapeutics targeting lncRNAs poses unique challenges due to their complex structures and functions.

Nevertheless, the burgeoning field of lncRNA research and the advent of high-throughput sequencing technologies present unprecedented opportunities to unravel the mysteries surrounding LOC100128028. Continued efforts to elucidate its role in disease pathogenesis and explore its therapeutic and diagnostic potential are essential.


LOC100128028, a fascinating yet enigmatic lncRNA, holds immense promise as a potential drug target or biomarker for various diseases, particularly cancer. Unraveling its precise function and deciphering the underlying molecular mechanisms will be crucial in harnessing its therapeutic benefits. Furthermore, utilizing LOC100128028 as a diagnostic tool could significantly advance disease diagnosis, prognostication, and treatment monitoring. The future of LOC100128028 research is promising, with many opportunities to exploit its potential for the betterment of healthcare.

Protein Name: Uncharacterized LOC100128028

The "LOC100128028 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC100128028 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

LOC100128050 | LOC100128059 | LOC100128079 | LOC100128093 | LOC100128164 | LOC100128242 | LOC100128288 | LOC100128317 | LOC100128361 | LOC100128398 | LOC100128494 | LOC100128593 | LOC100128770 | LOC100128966 | LOC100128988 | LOC100129034 | LOC100129098 | LOC100129148 | LOC100129175 | LOC100129203 | LOC100129215 | LOC100129316 | LOC100129381 | LOC100129434 | LOC100129455 | LOC100129534 | LOC100129603 | LOC100129697 | LOC100130000 | LOC100130207 | LOC100130285 | LOC100130298 | LOC100130331 | LOC100130452 | LOC100130463 | LOC100130548 | LOC100130587 | LOC100130691 | LOC100130698 | LOC100130744 | LOC100130748 | LOC100130872 | LOC100130899 | LOC100130938 | LOC100130987 | LOC100130992 | LOC100131096 | LOC100131107 | LOC100131257 | LOC100131289 | LOC100131372 | LOC100131496 | LOC100131532 | LOC100131626 | LOC100131635 | LOC100131859 | LOC100131877 | LOC100131943 | LOC100132004 | LOC100132062 | LOC100132077 | LOC100132078 | LOC100132249 | LOC100132287 | LOC100132356 | LOC100132609 | LOC100132626 | LOC100132651 | LOC100132686 | LOC100132741 | LOC100132781 | LOC100132797 | LOC100133077 | LOC100133165 | LOC100133177 | LOC100133284 | LOC100133331 | LOC100133920 | LOC100134317 | LOC100134368 | LOC100134391 | LOC100134868 | LOC100190986 | LOC100233156 | LOC100240728 | LOC100240734 | LOC100240735 | LOC100271840 | LOC100272216 | LOC100272217 | LOC100286922 | LOC100287036 | LOC100287290 | LOC100287329 | LOC100287413 | LOC100287792 | LOC100287834 | LOC100287846 | LOC100287944 | LOC100288069